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Insulin resistance, which is highly prevalent in the elderly, is
suggested to be accompanied by an increased acute phase
response. Until now, it is unclear whether cellular adhesion
molecules are involved in the clustering of insulin resistance.
In the present study, we examined the relationship of in-
sulin resistance (measured by postload insulin) with levels of
markers of inflammation and cellular adhesion molecules in
a random sample of 574 nondiabetic elderly men and women
participating in the Rotterdam Study. Associations were
assessed by regression analysis, with ln-insulin as the de-
pendent variable [regression coefficient (95% confidence
interval)].
In our population, insulin was strongly and significantly
(P < 0.001) associated with the markers of inflammation C-
reactive protein [1.52 (0.96–2.08)], -1-antichymotrypsin [1.25
(0.82–1.69)], and IL-6 [2.60 (1.69–3.52)], adjusted for age and
gender. Associations weakened, to some extent, after addi-
tional adjustment for measures of obesity, smoking, and car-
diovascular disease. Insulin was associated with the soluble
intercellular adhesion molecule 1 [2.22 (1.29–3.16; P < 0.001)],
whereas no association with the soluble vascular cell adhe-
sion molecule 1 was found. The strength of the associations of
insulin with C-reactive protein, -1-antichymotrypsin, IL-6,
and soluble intercellular adhesion molecule 1, as assessed by
standardized regression coefficients, was comparable with
the strength of the associations of insulin with high-density
lipoprotein cholesterol, body mass index, and waist-to-hip
ratio.
The results of this population-based study indicate that
low-grade inflammation and the cellular adhesion molecule
soluble intercellular adhesion molecule 1 are an integral part
of insulin resistance in nondiabetic elderly. These factors may
contribute to the well-known relationship between insulin
resistance and cardiovascular disease risk and might poten-
tially become therapeutic targets in insulin resistant subjects.
(J Clin Endocrinol Metab 86: 4398–4405, 2001)
THE INSULIN RESISTANCE syndrome involves cluster-ing of several metabolic cardiovascular disease risk
factors: raised insulin, dyslipidemia, obesity, increased ab-
dominal fat, and hypertension (1–3). Insulin resistance is
highly prevalent in the elderly (4) and is associated with
cardiovascular disease risk. Recent data suggest that inflam-
mation plays a crucial role in atherogenesis (5) and that also
insulin resistance may be accompanied by an increased
acute-phase response, both in subjects with (6) and without
diabetes mellitus (7, 8). A link between insulin resistance and
the inflammatory state is further suggested by increased
levels of the acute-phase proteins plasminogen activator in-
hibitor-1 and fibrinogen in the insulin resistance syndrome
(9, 10), and by the finding that dyslipidemia in the insulin
resistance syndrome and during the acute phase response
show strong similarities (11, 12).
Increased levels of circulating cellular adhesion molecules
have been shown among diabetic subjects, compared with
nondiabetic controls (13, 14). Cellular adhesion molecules
mediate the attachment and transmigration of leukocytes
across the endothelial surface in response to several inflam-
matory cytokines (15), and are hypothesized to play an im-
portant role in the initiation of atherosclerosis (16). Until
now, it is unclear whether cellular adhesion molecules are
involved in the clustering of insulin resistance.
To further clarify whether inflammation and endothelial
activation are an integral part of the insulin resistance syn-
drome, we cross-sectionally examined associations of levels
of markers of inflammation and cellular adhesion molecules
with insulin resistance (measured by postload insulin) in a
population of nondiabetic elderly men and women partici-
pating in the Rotterdam Study.
Subjects and Methods
Study population
The Rotterdam Study is a population-based cohort study aiming to
assess the occurrence of chronic diseases in an aging population and to
clarify their determinants (17). The cohort includes 3105 men and 4878
women, 55 yr old and older (78% of the eligible population), living in
a defined district in Rotterdam, The Netherlands. Baseline data were
Abbreviations: ACT, -1-Antichymotrypsin; BMI, body mass index;
CI, confidence interval; CRP, C-reactive protein; ECG, electrocardio-
gram; HDL, high-density lipoprotein; PAD, peripheral arterial disease;
sICAM-1, soluble intercellular adhesion molecule 1; sVCAM-1, soluble
vascular cell adhesion molecule 1; WHO, World Health Organization;
WHR, waist-to-hip ratio.
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collected from August 1990 until July 1993. Information on current and
past health, medication, lifestyle, and risk factors for chronic diseases
was gathered during a home interview by a trained research assistant.
The participants were subsequently invited to a research center for
clinical examination. The study was approved by the Medical Ethics
Committee of the Erasmus Medical Center Rotterdam, Rotterdam, The
Netherlands.
Levels of inflammatory markers and cellular adhesion molecules
were determined in plasma in a gender-stratified random sample of 720
subjects. As part of the Rotterdam Study, glucose metabolism was stud-
ied using a nonfasting oral glucose tolerance test. Within the sample of
720 subjects, postload insulin levels were available for 602 participants
not prescribed glucose-lowering medication. Because postload insulin is
not considered to be a valid measure of insulin resistance in diabetic
subjects, subjects with newly diagnosed diabetes mellitus on basis of
postload serum glucose levels (11.1 mm, n  28) were excluded,
leaving a population of 574 nondiabetic subjects. Given gender distri-
bution, the prevalence of cardiovascular disease risk factors in the 574
subjects was comparable with the prevalence of these risk factors in the
total nondiabetic population of the Rotterdam Study.
Clinical examination and laboratory methods
Height, weight, and waist and hip circumferences were measured
while the study participants wore indoor clothes without shoes. Body
mass index (BMI, weight divided by height squared) and waist-to-hip
ratio (WHR) were computed. Sitting systolic and diastolic blood pres-
sures were measured with a random-zero sphygmomanometer by a
trained research assistant, after a 5-min rest, and a standard 12-lead
electrocardiogram (ECG) was obtained (ACTA ECG recorder, Esoate,
Florence, Italy). The presence of peripheral arterial disease (PAD) was
evaluated by measuring the systolic blood pressure of the posterior tibial
artery at both the right and the left leg using an 8-MHz continuous-wave
Doppler probe (Huntleigh 500 D, Huntleigh Technology, Bedfordshire,
UK) and a random-zero sphygmomanometer. For each leg, a single
blood pressure reading was taken with the subject in the supine position.
The ratio of the systolic blood pressure at the ankle to the systolic blood
pressure at the arm was calculated for each leg.
A venipuncture was performed, and nonfasting blood samples were
obtained and were directly put on ice. Serum samples were processed
within 30 min, after which they were kept frozen at 20 C. We used an
automated enzymatic procedure to determine serum total cholesterol
level (18). High-density lipoprotein (HDL) cholesterol was measured
similarly, after precipitation of the non-HDL fraction. All participants
not prescribed glucose-lowering medication received a glucose drink of
75 g in 200 mL water after a first venipuncture. Two hours later, a second
venous blood sample was obtained. Glucose levels were determined in
both blood samples by the glucose hexokinase method, whereas insulin
was measured by RIA (Medgenix Diagnostics, Brussels, Belgium). This
assay has a cross-reactivity with proinsulin of 40%. Because subjects
using glucose-lowering medication did not undergo the glucose toler-
ance test, insulin was not measured in this group. The coefficients of
variation of glucose and insulin measurements were less than 2.5% and
6.0%, respectively.
Levels of inflammatory markers and cellular adhesion molecules
were measured in plasma. For the collection of plasma, blood was
collected in tubes containing 0.129 m sodium citrate. All tubes were
stored on ice before and after blood sampling. Plasma was obtained by
centrifugation of 30 min, at 10,000 rotations/min, at 10 C, and was
immediately frozen in liquid nitrogen and stored at 80 C. Plasma
concentrations of C-reactive protein (CRP) and -1-antichymotrypsin
(ACT) were measured by kinetic nephelometry (Behring Nephelometer
BN200, Marburg, Germany) after a 5 dilution using Behring’s N-
dilutent. Levels of IL-6, soluble intercellular adhesion molecule 1
(sICAM-1), and soluble vascular cell adhesion molecule 1 (sVCAM-1)
were determined by means of enzyme-linked immunosorbent assay
(IL-6: Quantikine; sICAM-1 and sVCAM-1: Parameter, R&D Systems
Europe, Oxon, United Kingdom). Interassay coefficients of variation
were 4.4%, 2.8%, 8.7%, 6.9%, and 5.0% for CRP, ACT, IL-6, sICAM-1, and
s-VCAM, respectively. Corresponding intraassay coefficients of varia-
tion were 2.6%, 3.7%, 5.7%, 5.0%, and 3.1%, respectively. For 16, 16, 6,
3, and 3 subjects, respectively, we could not determine levels of CRP,
ACT, IL-6, sICAM-1, and sVCAM-1 because of insufficient plasma for
analysis. Levels of CRP, ACT, IL-6, sICAM-1, and sVCAM-1 were there-
fore available for analysis in the following number of subjects: 562 (265
men, 297 women), 562 (264 men, 298 women), 570 (271 men, 299 women),
571 (271 men, 300 women), and 572 (271 men, 301 women), respectively.
Metabolic disorders
Diabetes mellitus was defined as the use of glucose-lowering med-
ication or a random or postload serum glucose level  11.1 mm accord-
ing to the World Health Organization (WHO) criteria (19). Impaired
glucose tolerance was considered present when the postload serum
glucose level was between 7.8 and 11.1 mm in subjects without diabetes
mellitus (4). Postload insulin was used as a measure of insulin resistance.
Dyslipidemia was defined as a total cholesterol level  8.0 mm, and/or
an HDL cholesterol level  0.9 mm (20), and/or use of lipid lowering
medication. We defined obesity as BMI  30.0 kg/m2 in both genders,
and/or waist circumference  102 cm in men, and/or waist circum-
ference 88 cm in women according to WHO criteria (21). Hypertension
was defined as systolic blood pressure  160 mm Hg and/or diastolic
blood pressure  100 mm Hg and/or use of antihypertensive medica-
tion, encompassing grade 2 and grade 3 hypertension according to WHO
criteria (22).
Prevalent cardiovascular disease
The presence of myocardial infarction was assessed by self-report and
by analysis of the standard 12-lead ECGs, which were stored digitally
and analyzed by the modular ECG analysis system (23, 24). From sub-
jects with self-reported myocardial infarction without ECG evidence, we
collected additional information from the general practitioner or cardi-
ologist, and myocardial infarction was confirmed if the information in
the medical records met standard diagnostic criteria. From subjects
without self-reported myocardial infarction but with ECG evidence, in
whom the absence of symptoms was confirmed by reviewing the med-
ical records, ECGs were reviewed by an experienced cardiologist, and
(silent) myocardial infarction was included when the ECG met standard
diagnostic criteria for myocardial infarction. We combined both types of
myocardial infarctions to one variable for the analyses (25). Information
on a history of coronary artery bypass graft or percutaneous translu-
minal coronary angioplasty was obtained during the interview. A his-
tory of stroke was determined on the basis of interview data and medical
information from the general practitioner or from hospital discharge
records (26). PAD was considered to be present if the ankle-arm systolic
blood pressure index was less than 0.90 in either leg (27).
Statistical analysis
To obtain normal distributions, insulin, CRP, and IL-6 were natural-
log transformed (ln-transformation).
The associations between levels of postload insulin and markers of
inflammation and cellular adhesion molecules were assessed by sepa-
rate linear regression models with ln-insulin as the dependent variable
and with levels of markers of inflammation and cellular adhesion mol-
ecules as independent variables. Associations were examined for the
total population and for men and women separately. Models were
initially adjusted for age and, if appropriate, gender. In subsequent
models, we additionally adjusted for BMI, WHR, smoking (never,
former, current), and presence of cardiovascular disease.
Furthermore, multivariate-adjusted levels of markers of inflamma-
tion and cellular adhesion molecules were assessed in tertiles of levels
of postload insulin. For these analyses, we constructed variables with the
values 1–3 for subsequent tertiles of levels of postload insulin for the
total population, and for men and women separately. These variables
were entered in general linear models as continuous independent vari-
ables with levels of markers of inflammation and cellular adhesion
molecules as dependent variables. Tests of significance for the coeffi-
cients of the ordered variables of insulin were considered to be tests for
trend.
Subsequently, we compared the strength of the associations of post-
load insulin with markers of inflammation and cellular adhesion mol-
ecules to the strength of the associations of insulin with variables clas-
sically considered to be clustered within the insulin resistance
syndrome. For this endeavor, we performed separate linear regression
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analyses with postload ln-insulin as the dependent variable and levels
of markers of inflammation, cellular adhesion molecules, and HDL
cholesterol, BMI, WHR, and systolic blood pressure as independent
variables, and presented standardized regression coefficients of multi-
variate-adjusted analyses.
In addition, we computed levels of markers of inflammation and
cellular adhesion molecules in subjects according to the presence of the
number of metabolic disorders known to be clustered within the insulin
resistance syndrome: impaired glucose tolerance, dyslipidemia, obesity,
and hypertension. For these analyses we constructed a variable with
value 0–4 according to the number of metabolic disorders present. This
variable was entered in general linear models as a continuous indepen-
dent variable, with levels of markers of inflammation and cellular ad-
hesion molecules as dependent variables. Tests of significance for the
coefficients of the ordered variable of the number of metabolic disorders
present were considered to be tests for trend.
We considered P-values 0.05 to be statistically significant. SPSS 9.0
for Windows (SPSS Inc., Chicago, IL) was used for all analyses.
Results
Characteristics of the population are described in Table 1.
Levels of CRP ranged from 0.01–48.7 mg/liter; 35 subjects
had values greater than 10 mg/liter, the cut-point generally
used to identify clinically relevant inflammation.
Correlations between the levels of the three markers of
inflammation were moderate; CRP–IL-6 r  0.53, CRP–ACT
r  0.40, ACT–IL-6 r  0.26, P  0.001, adjusted for age and
gender. The levels of CRP, ACT, and IL-6 were strongly
associated with levels of postload insulin (Table 2). Associ-
ations with CRP tended to be somewhat stronger in women
than in men. Multivariate adjustment decreased the strength
of the associations to some extent (Table 2). Adjusting the
association between CRP and postload insulin for the other
two inflammatory markers removed the association ( 
0.42, P 0.23), whereas the effect of controlling for the other
two inflammatory markers on the strength of the association
between ACT and insulin, and IL-6 and insulin was less
pronounced ( 0.95, and  1.87, P  0.001, respectively,
adjusted for age and gender). Levels of the cellular adhesion
molecule sICAM-1 were associated with levels of CRP, ACT,
and IL-6 (correlation coefficients r  0.28, r  0.20, and r 
0.24, respectively, all P  0.001), whereas no associations
between levels of sVCAM-1 and levels of markers of inflam-
mation were found (r 0.05, r0.02, r 0.08, respectively,
not statistically significant), all adjusted for age and gender.
Levels of sICAM-1 showed a strong association with post-
load insulin as well, whereas levels of sVCAM-1 did not
(Table 2). Adjustment of the associations between levels of
sICAM-1 and postload insulin for levels of CRP, ACT, or IL-6
did not materially affect the results (data not shown). Levels
of sICAM-1 were associated with other parameters of the
insulin resistance syndrome, namely WHR (r  0.09, P 
0.045) and HDL cholesterol (r  0.15, P  0.001), adjusted
for age and gender, whereas levels of sVCAM-1 were not (r
0.06 and0.05, respectively, not statistically significant). Ex-
clusion of subjects with impaired glucose tolerance slightly
weakened the strength of the described associations (data not
shown). Exclusion of subjects with levels of CRP more than
10 mg/liter did not affect the results (data not shown). As-
TABLE 1. Clinical and biochemical characteristics of the study population
Variable All subjects, n  574 Men, n  272 Women, n  302
Age, yr 70.2  8.9 69.7  8.3 70.7  9.3
BMI, kg/m2 26.4  3.4 25.9  2.8 26.8  3.8
Waist circumference, cm 91  11 94  9 87  11
WHR, cm/cm 0.91  0.09 0.96  0.07 0.87  0.08
Obesity, % (n)a 32 (181) 18 (50) 43 (131)
Smoking status, % (n)
Never 34 (198) 9 (25) 57 (173)
Past 44 (250) 64 (174) 25 (76)
Current 22 (126) 27 (73) 18 (53)
Systolic blood pressure, mm Hg 139  21 138  20 139  22
Diastolic blood pressure, mm Hg 73  11 74  11 73  11
Hypertension, % (n)b 26 (147) 24 (65) 27 (82)
Total cholesterol, mM 6.6  1.2 6.3  1.2 6.9  1.2
HDL cholesterol, mM 1.3  0.4 1.2  0.4 1.5  0.3
Dyslipidemia, % (n)c 24 (135) 26 (70) 21 (65)
Glucose, mmol/liter 6.4  1.6 6.2  1.6 6.6  1.6
Postload insulin, mU/literd 52.7 (31.0–76.0) 51.0 (29.0–73.0) 53.0 (35.0–81.0)
Impaired glucose tolerance, % (n)e 19 (107) 14 (37) 23 (70)
Cardiovascular disease, % (n)f 22 (127) 23 (63) 21 (64)
CRP, mg/literd,g 1.6 (0.8–3.5) 1.4 (0.7–3.6) 1.8 (0.8–3.4)
ACT, mg/dlg 47.1  14.0 46.1  14.1 48.0  13.8
IL-6, pg/mld,g 1.8 (1.2–3.0) 1.9 (1.4–3.1) 1.7 (1.2–2.8)
sICAM-1, ng/mlg 220.9  64.6 224.4  72.5 217.7  56.5
sVCAM-1, ng/mlg 541.8  180.8 547.6  169.5 536.5  190.5
Data are mean  SD, median (interquartile range) for variables with skewed distributions, or percentages (number of subjects).
a BMI  30.0 kg/m2 in both genders, and/or waist circumference  102 cm in men, and/or waist circumference  88 cm in women.
b Systolic blood pressure  160 mm Hg and/or diastolic blood pressure  100 mm Hg, and/or use of antihypertensive medication.
c Total cholesterol level  8.0 mM, and/or HDL cholesterol level  0.9 mM, and/or use of lipid lowering medication.
d Skewed data.
e Postload serum glucose between 7.8 and 11.1 mM in subjects without diabetes mellitus.
f Presence of PAD and/or history of myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft,
or stroke.
g Levels of CRP, ACT, IL-6, sICAM-1, and sVCAM-1 were available in the following numbers of subjects: 562 (265 men, 297 women), 562
(264 men, 298 women), 570 (271 men, 299 women), 571 (271 men, 300 women), and 572 (271 men, 301 women), respectively.
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sociations between postload insulin and levels of markers of
inflammation and sICAM-1 were still present after exclusion
of subjects with prevalent cardiovascular disease (data not
shown).
Multivariate-adjusted levels of CRP, ACT, IL-6, and
sICAM-1 increased in subsequent tertiles of levels of post-
load insulin (Fig. 1). All tests for trend were statistically
significant, except for the trend analyses regarding the as-
sociation between tertiles of levels of postload insulin and
CRP and sICAM-1 in men. Additional adjustment of the
levels of sICAM-1 in tertiles of levels of postload insulin for
markers of inflammation did not materially affect the results
(data not shown). Again, we found no association between
levels of sVCAM-1 and levels of postload insulin.
The strengths of the multivariate-adjusted associations be-
tween levels of postload insulin and CRP, ACT, IL-6, and
sICAM-1, as expressed by standardized regression coeffi-
cients, were comparable with the strengths of the associa-
tions between levels of insulin and HDL cholesterol, BMI,
and WHR (Table 3). Adjustment of the association between
levels of postload insulin and sICAM-1 for levels of markers
of inflammation again did not materially affect the results
(data not shown). In our population, no association between
systolic blood pressure and postload insulin was found.
The number of subjects categorized in categories 0–4 in-
dicating the number of metabolic disorders present was 192,
232, 111, 31, and 5, respectively. Because of missing data, 3
subjects could not be categorized accordingly. Because of the
low number of subjects with 3 or 4 metabolic disorders, we
combined these categories into 1 category for analyses. Mul-
tivariate-adjusted levels of CRP, ACT, IL-6, and levels of
sICAM-1 increased with the increasing number of metabolic
disorders present (Fig. 2). All tests for trend reached statis-
tical significance. Additional adjustment of levels of
sICAM-1 according to the number of metabolic disorders for
markers of inflammation did not materially affect the results
(data not shown). No association was found between levels
of sVCAM-1 and the number of metabolic disorders present.
After stratification by gender, results were comparable with
those presented for the total population, apart from CRP in
men (ptrend  0.34), and sICAM-1 in women (ptrend  0.17)
(data not shown).
Discussion
Our results indicate that, in an elderly population, markers
of inflammation are strongly and independently associated
with insulin resistance, as measured by postload insulin. In
addition, the cellular adhesion molecule sICAM-1 is associ-
ated with insulin, whereas sVCAM-1 is not.
Some methodological issues should be taken into account
when interpreting our results. Nonfasting postload insulin
was used as a measure of insulin resistance. Previous results
from the Rotterdam Study indicate that these levels are sim-
ilar to fasting postload levels (28), and it is shown that post-
load insulin provides a good measure of insulin resistance in
subjects without diabetes mellitus (29). If anything, the va-
lidity of our results does not depend on the precision of the
measurement of insulin resistance used. The immunoassay
used to measure insulin is known to cross-react with pro-
insulin. Although proinsulin is increased in impaired glu-
cose tolerance, it constitutes only a minor part of the total
insulin measured (30) and is therefore probably not respon-
sible for the observed association with levels of markers of
inflammation and cellular adhesion molecules. Levels of
markers of inflammation and cellular adhesion molecules
TABLE 2. Regression coefficients for ln-insulina as the dependent variable and markers of inflammation and cellular adhesion molecules
as independent variables
All subjects Men Women
b 95% CI b 95% CI b 95% CI
CRP, mg/literc
Model 1d 1.52 (0.96; 2.08) 1.10 (0.26; 1.94) 1.97 (1.22; 2.72)
Model 2e 0.88 (0.24; 1.51) 0.43 (0.49; 1.35) 1.40 (0.49; 2.30)
ACT, 100 mg/dl
Model 1d 1.25 (0.82; 1.69) 1.26 (0.60; 1.92) 1.28 (0.70; 1.85)
Model 2e 1.09 (0.62; 1.60) 1.18 (0.48; 1.87) 1.09 (0.42; 1.75)
IL-6, pg/mlc
Model 1d 2.60 (1.69; 3.52) 2.60 (1.26; 3.94) 2.62 (1.37; 3.87)
Model 2e 1.91 (0.92; 2.90) 2.02 (0.62; 3.42) 1.88 (0.46; 3.31)
sICAM-1, 1 g/ml
Model 1d 2.22 (1.29; 3.16) 2.10 (0.85; 3.36) 2.44 (1.01; 3.87)
Model 2e 1.94 (0.96; 2.92) 1.57 (0.24; 2.90) 2.26 (0.77; 3.76)
sVCAM-1, 10 g/ml
Model 1d 1.78 (1.72; 5.27) 2.45 (3.23; 8.12) 1.30 (3.11; 5.71)
Model 2e 0.75 (3.07; 4.56) 0.64 (5.26; 6.55) 0.91 (4.13; 5.95)
a Postload insulin.
b  indicates regression coefficient; an increase of the independent variable by 1 U is associated with an increase of insulin by a factor e.
c CRP and IL-6 were ln-transformed to obtain a better model fit as assessed by residual analysis; an increase of CRP and IL-6 by 1% yield
an increase of postload insulin by 0.1 %.
d Model 1. Adjusted for age, and, if appropriate, gender. Number of subjects in models with CRP, ACT, IL-6, sICAM-1, and sVCAM-1 were
562 (265 men, 297 women), 562 (264 men, 298 women), 570 (271 men, 299 women), 571 (271 men, 300 women), and 572 (271 men, 301 women),
respectively.
e Model 2. Adjusted for age, BMI, WHR, smoking (never, former, current), presence of cardiovascular disease, and, if appropriate, gender.
Numbers of subjects in models with CRP, ACT, IL-6, sICAM-1, and sVCAM-1 were 486 (230 men, 256 women), 486 (229 men, 257 women),
494 (235 men, 259 women), 495 (235 men, 260 women), and 495 (235 men, 260 women), respectively.
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were measured in a gender-stratified random sample of sub-
jects representative of the participants of the Rotterdam
Study. We do assume that the sampling of subjects will not
depend on the associations between insulin and levels of
markers of inflammation and cellular adhesion molecules,
making selection bias unlikely.
The results of our study are in line with recent results from
the Insulin Resistance Atherosclerosis Study, in which CRP,
fibrinogen, and white cell count were found to be associated
with fasting insulin in nondiabetic subjects (7). In healthy
middle-aged subjects, CRP was found to be related to insulin
resistance as well (8). Also, in subjects with type 2 diabetes
mellitus, an elevated acute-phase response was particularly
marked in those with features of the metabolic syndrome (6).
Factor analysis of data on healthy elderly people from the
Cardiovascular Health Study, however, found inflammatory
variables only weakly linked to insulin resistance (31).
The etiology of the clustering of metabolic factors in the
FIG. 1. Multivariate-adjusted (a) mean levels [95% confidence interval (CI)] of markers of inflammation and cellular adhesion molecules
according to tertiles of levels of postload insulin (b) in the total population, and in men and women separately. a, Adjusted for age, BMI, WHR,
smoking (never, former, current), presence of cardiovascular disease, and, if appropriate, gender. Multivariate-adjusted levels of CRP, ACT,
IL-6, sICAM-1, and sVCAM-1 were available in the following numbers of subjects: 486 (230 men, 256 women), 486 (229 men, 257 women), 494
(235 men, 259 women), 495 (235 men, 260 women), and 495 (235 men, 260 women), respectively. b, Tertiles of levels of insulin were computed
for the total population, and for men and women separately. c, Geometric mean values (95% CI) because of skewed data.
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insulin resistance syndrome remains controversial. A com-
mon view is that insulin resistance, with its compensatory
hyperinsulinemia, is the underlying mechanism (1). Alter-
natively, abdominal obesity may be the primary defect of the
clustering (2). Our data, and those of others (6–8), give sup-
port to the hypothesis that raised concentrations of proin-
flammatory cytokines, originating from various cells, and
the resultant acute-phase response may underlie much of the
metabolic clustering (32). Furthermore, a key role for the
cytokine TNF, which induces hepatic synthesis of acute-
phase proteins (33), has been suggested in the pathogenesis
of insulin resistance. TNF increases serum triglycerides and
very-low-density lipoprotein; stimulates insulin-indepen-
dent glucose use, while inhibiting stimulated glucose uptake
by fat and muscle; and causes an increase in counterregu-
latory hormones (34). Moreover, TNF plays a role as a
mediator of peripheral insulin resistance in obesity by in-
hibiting the tyrosine kinase activity of the insulin receptor
and its substrate (35). The cross-sectional nature of the design
of our study complicates etiological interpretation of the
results. However, prospective data showed markers of in-
flammation to be associated with the development of dia-
betes mellitus, probably reflecting the pathogenesis of type
2 diabetes (36).
An alternative explanation for the association between
insulin and levels of markers of inflammation might be the
presence of atherosclerosis, which is associated with both
insulin resistance and markers of inflammation (37). In our
population, however, associations between insulin and lev-
els of markers of inflammation were still present after ad-
justment for presence of cardiovascular disease (Table 2,
model 2) and after exclusion of subjects with prevalent car-
diovascular disease (data not shown). This suggests that
atherosclerosis did not induce the association between in-
sulin resistance and markers of inflammation. However, be-
cause we adjusted only for presence of cardiovascular dis-
ease, the assessment of degree and extent of atherosclerosis
might lack accuracy in this respect. Furthermore, we have to
consider the possibility that decreased insulin sensitivity
leads to, rather than is the consequence of, raised concen-
trations of inflammatory mediators. Insulin inhibits acute-
phase protein synthesis in human hepatoma cell lines (38),
suggesting that insulin resistance might amplify the cytokine
effect on the liver.
We are the first to describe an association between insulin
and levels of the cellular adhesion molecule sICAM-1, which
has been found to be associated with increased risk for future
coronary events (39, 40). In our population, the cellular ad-
hesion molecule sVCAM-1 was not associated with insulin.
Previous results in healthy men participating in the Physi-
cian’s Health Study describe associations of sICAM-1 with
several metabolic cardiovascular risk factors encompassed in
the insulin resistance syndrome, such as triglycerides, HDL
cholesterol, fibrinogen, and hypertension (41). In dyslipide-
mic patients, increased levels of sICAM-1 and sVCAM-1
were found as well (42).
Levels of sICAM-1 were associated with levels of markers
of inflammation. Adjustment of the association between in-
sulin and sICAM-1 for CRP, ACT, or IL-6, however, did not
materially affect the results. These results may indicate that
inflammation is not the principal mechanism linking insulin
and endothelial activation in our population (15, 43). Het-
erogeneity of markers of low-grade inflammation may have
played a role in these findings as well. Another mechanism
explaining the association between insulin and levels of
sICAM-1 may be increased oxidation of LDL cholesterol (44).
Moreover, a direct effect of glucose or insulin on the expres-
sion of cellular adhesion molecules has been demonstrated
in rabbits (45). On the other hand, we have to consider the
possibility that the association between insulin and sICAM-1
may be induced by atherosclerosis, which has been shown to
be associated with higher levels of sICAM-1 (39). Associa-
tions, however, remained after adjustment for the presence
of cardiovasular disease (Table 2, model 2) and were equally
present in subjects without prevalent cardiovasular disease
(data not shown). Further studies should determine whether
our observation can be confirmed. An understanding of the
role of cellular adhesion molecules in insulin resistance may
lead to a potential target for prevention or treatment of ath-
erosclerosis. Recently, for example, antibodies to ICAM-1
TABLE 3. Multivariate-adjusteda standardized regression coefficients for ln-insulinb as the dependent variable and markers of
inflammation and cellular adhesion molecules and factors classically associated with insulin resistance as independent variables
All subjects Men Women
c P value c P value c P value
CRP, mg/literd,e 0.12 0.007 0.062 0.36 0.20 0.003
ACT, mg/dld 0.20 0.001 0.21 0.001 0.20 0.001
IL-6, pg/mld,e 0.18 0.001 0.19 0.005 0.17 0.010
sICAM-1, ng/mld 0.17 0.001 0.14 0.021 0.18 0.003
sVCAM-1, ng/mld 0.017 0.70 0.014 0.83 0.022 0.72
HDL cholesterol, mMd 0.13 0.003 0.090 0.14 0.17 0.004
BMI, kg/m2d 0.14 0.002 0.23 0.002 0.10 0.09
WHR, cm/cmd 0.25 0.001 0.16 0.019 0.24 0.001
Systolic blood pressure, mm Hgd 0.031 0.49 0.060 0.35 0.008 0.90
a Adjusted for age, BMI (apart from model with BMI as independent variable), WHR (apart from model with WHR as independent variable),
smoking (never, former, current), presence of cardiovascular disease, and, if appropriate, gender.
b Postload insulin.
c  indicates standardized regression coefficient.
d Number of subjects in models with CRP, ACT, IL-6, sICAM-1, sVCAM-1, and HDL cholesterol to systolic blood pressure were 486 (230 men,
256 women), 486 (229 men, 257 women), 494 (235 men, 259 women), 495 (235 men, 260 women), 495 (235 men, 260 women), and 574 (272 men,
302 women), respectively.
e CRP and IL-6 were ln-transformed to obtain a better model fit as assessed by residual analysis.
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have been shown to reverse atherogenesis in hypercholes-
terolemic rabbits (46).
In summary, our results indicate that insulin is strongly
and independently associated with markers of inflammation
and the cellular adhesion molecule sICAM-1, suggesting that
subclinical inflammation and endothelial activation are an
integral part of the insulin resistance syndrome. These factors
may contribute to the well-known relationship between in-
sulin resistance and cardiovascular disease risk. Moreover,
antiinflammatory treatment and strategies aimed at antag-
onizing effects of cellular adhesion molecules may possibly
gain clinical importance in the treatment of insulin resistance
and its complications.
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